NASDAQ:CASI - Nasdaq - KYG1933S1012 - Common Stock - Currency: USD
NASDAQ:CASI (6/3/2025, 4:30:02 PM)
1.86
+0.01 (+0.67%)
The current stock price of CASI is 1.86 USD. In the past month the price decreased by -2.87%. In the past year, price decreased by -46.4%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.23 | 330.76B | ||
AMGN | AMGEN INC | 13.95 | 155.70B | ||
GILD | GILEAD SCIENCES INC | 14.13 | 136.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.66B | ||
REGN | REGENERON PHARMACEUTICALS | 11.01 | 52.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.61B | ||
ARGX | ARGENX SE - ADR | 100.28 | 35.21B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.80B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.45 | 27.21B | ||
NTRA | NATERA INC | N/A | 21.87B | ||
BIIB | BIOGEN INC | 8.33 | 19.32B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.31B |
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The firm is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
CASI PHARMACEUTICALS INC
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District
Beijing BEIJING 20850 CN
CEO: Wei-Wu He
Employees: 233
Phone: 861065618789
The current stock price of CASI is 1.86 USD. The price increased by 0.67% in the last trading session.
The exchange symbol of CASI PHARMACEUTICALS INC is CASI and it is listed on the Nasdaq exchange.
CASI stock is listed on the Nasdaq exchange.
7 analysts have analysed CASI and the average price target is 4.08 USD. This implies a price increase of 119.35% is expected in the next year compared to the current price of 1.86. Check the CASI PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CASI PHARMACEUTICALS INC (CASI) has a market capitalization of 28.81M USD. This makes CASI a Nano Cap stock.
CASI PHARMACEUTICALS INC (CASI) currently has 233 employees.
CASI PHARMACEUTICALS INC (CASI) has a resistance level at 1.95. Check the full technical report for a detailed analysis of CASI support and resistance levels.
The Revenue of CASI PHARMACEUTICALS INC (CASI) is expected to decline by -5.03% in the next year. Check the estimates tab for more information on the CASI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CASI does not pay a dividend.
CASI PHARMACEUTICALS INC (CASI) will report earnings on 2025-08-14.
CASI PHARMACEUTICALS INC (CASI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.51).
The outstanding short interest for CASI PHARMACEUTICALS INC (CASI) is 0.22% of its float. Check the ownership tab for more information on the CASI short interest.
ChartMill assigns a fundamental rating of 1 / 10 to CASI. CASI has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months CASI reported a non-GAAP Earnings per Share(EPS) of -2.51. The EPS decreased by -10.09% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -99.16% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to CASI. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 19.14% and a revenue growth -5.03% for CASI